Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Teva
McKinsey
QuintilesIMS
US Department of Justice
Chinese Patent Office

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,747,896

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,747,896 protect, and when does it expire?

Patent 8,747,896 protects SITAVIG and is included in one NDA.

This patent has thirty-one patent family members in twenty-six countries.

Summary for Patent: 8,747,896
Title:Mucosal bioadhesive slow release carrier for delivering active principles
Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
Inventor(s): Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee: BioAlliance Pharma (Paris, FR)
Application Number:13/565,653
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Use;

Drugs Protected by US Patent 8,747,896

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF HERPES LABIALIS   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,747,896

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06290480Mar 24, 2006

International Family Members for US Patent 8,747,896

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 060085   Try a Free Trial
Austria 446743   Try a Free Trial
Australia 2007231029   Try a Free Trial
Brazil PI0709057   Try a Free Trial
Canada 2647123   Try a Free Trial
China 101410092   Try a Free Trial
Cyprus 1109723   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
Covington
Teva
Cipla
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.